Apolipoprotein A-1 (ApoA-1) Test
The ApoA-1 test measures serum apolipoprotein A-1, the principal structural protein of HDL and the ligand driving reverse cholesterol transport. It indexes the pool of protective HDL particles more directly than HDL-cholesterol and, read with apolipoprotein B as the ApoB:ApoA-1 ratio, refines atherosclerotic cardiovascular risk assessment, especially in metabolic syndrome and discordant lipid…
2
Biomarkers
Blood (serum)
Sample
1–3 business days
Turnaround
No
Fasting
What is the ApoA-1 test?
The Apolipoprotein A-1 (ApoA-1) Test measures the serum concentration of the dominant structural protein of HDL, the particle responsible for carrying excess cholesterol back from the periphery to the liver. Rather than quantifying the cholesterol an HDL particle is transporting, as the familiar HDL-cholesterol does, it counts the protective particles themselves, providing a more stable index of reverse-cholesterol-transport capacity. Practitioners order it when a refined read of residual cardiovascular risk is wanted, particularly where standard lipid fractions give an incomplete picture. Within the cardiovascular work-up ApoA-1 is seldom interpreted alone. Its full value emerges when paired with apolipoprotein B to form the ApoB:ApoA-1 ratio, which weighs atherogenic particle number against protective particle number in a single figure that has proven a powerful risk discriminator in large international cohorts. Clinicians reach for apolipoprotein testing when discordance is suspected between LDL-cholesterol and true particle burden, when metabolic syndrome or hypertriglyceridaemia distorts the conventional panel, or when stratifying intermediate-risk patients for whom treatment intensity is uncertain.
What does the ApoA-1 test measure?
Apolipoprotein A-1 is a 243-residue amphipathic protein synthesised chiefly in the liver and small intestine. It is the principal structural scaffold of high-density lipoprotein, accounting for roughly two-thirds of HDL protein mass, and it gives the particle its functional identity. Beyond holding the particle together, ApoA-1 activates lecithin-cholesterol acyltransferase (LCAT) to esterify cholesterol within the maturing HDL core and serves as the ligand that docks onto the ABCA1 transporter to accept free cholesterol effluxed from peripheral cells, including lipid-laden macrophages in the arterial wall. In this way it is the molecular engine of reverse cholesterol transport.
Because each HDL particle carries ApoA-1 but a variable cholesterol cargo, serum ApoA-1 indexes the pool of atheroprotective particles more directly than HDL-cholesterol, which simply weighs the sterol they happen to be carrying. A low ApoA-1 marks diminished reverse-cholesterol-transport capacity and tracks with heightened atherosclerotic risk; its value is greatest when read against apolipoprotein B as the ApoB:ApoA-1 ratio, a single figure that contrasts the atherogenic particle burden with the protective one.
The ratio sets the number of atherogenic, ApoB-bearing particles (LDL, VLDL, IDL, Lp(a) and remnants, one ApoB per particle) against the number of protective ApoA-1-bearing HDL particles. It is a derived marker calculated from the two measured apolipoproteins rather than an independently assayed analyte, and it does not require fasting because neither component is meaningfully affected by a recent meal.
Large prospective datasets position the ApoB:ApoA-1 ratio among the strongest lipid-based discriminators of myocardial infarction risk, often outperforming conventional cholesterol fractions. It condenses the balance between pro- and anti-atherogenic particle counts into one number that is informative even when LDL-cholesterol is unremarkable, as in insulin resistance with small dense LDL.
Why is the ApoA-1 test ordered?
- Refinement of cardiovascular risk in intermediate-risk patients where LDL-cholesterol alone leaves treatment intensity uncertain
- Assessment of patients with insulin resistance, type 2 diabetes, or metabolic syndrome, in whom small dense LDL causes LDL-cholesterol to understate atherogenic particle number
- Evaluation of suspected discordance between standard lipid fractions and true particle burden, reported alongside apolipoprotein B
- Characterisation of hypertriglyceridaemia or mixed dyslipidaemia, where HDL-cholesterol is an unreliable guide to protective particle count
- Investigation of a low HDL-cholesterol to distinguish a genuinely reduced particle pool from a cholesterol-poor one
- Work-up of suspected familial HDL deficiency or Tangier disease, where ApoA-1 is characteristically very low, interpreted with specialist input
- Serial monitoring of the ApoB:ApoA-1 ratio as a composite marker of response to lifestyle and lipid-modifying therapy
- Risk stratification of patients with a strong family history of premature coronary disease despite near-normal conventional lipids
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
1–3 business days
Collection notes
Phlebotomy via LabCorp's patient service centre; no special preparation is required for ApoA-1 itself. Fasting is unnecessary for the apolipoprotein measurement, though a concurrently ordered lipid panel may call for a 9–12 hour fast. Note recent acute illness, pregnancy, oestrogen or androgen use, and alcohol intake on the requisition, as each shifts the result.
Specimen requirements
Serum (gel separator acceptable); minimum volume per LabCorp's current requirement. Separate from cells promptly and avoid grossly lipaemic or haemolysed specimens, which can interfere with the immunoassay. Record the performing laboratory for serial comparability, as apolipoprotein intervals are platform-specific.
What can affect ApoA-1 results?
ApoA-1 behaves as a negative acute-phase reactant; acute infection, recent surgery, trauma, or a flare of inflammatory disease transiently lowers it and can understate the habitual protective pool.
Regular moderate alcohol consumption raises hepatic ApoA-1 production and HDL particle number, so a recent drinking pattern can lift the measured value independent of long-term cardiovascular risk.
Oestrogen increases hepatic apolipoprotein A-1 synthesis, so pregnancy and oestrogen-containing therapy raise ApoA-1 and should be noted when interpreting a result.
Severely lipaemic serum can interfere with turbidimetric and nephelometric immunoassays, so grossly turbid specimens may need clearing or dilution and results read with caution.
Androgenic steroids suppress hepatic ApoA-1 output and lower HDL particle number, so a history of anabolic use can produce a low result that reflects exposure rather than baseline risk.
Both are associated with lower ApoA-1 and HDL particle concentrations; conversely, sustained aerobic activity tends to raise ApoA-1, so lifestyle context frames serial interpretation.
What do ApoA-1 results mean?
Elevated
A high ApoA-1 generally reflects a larger pool of protective HDL particles and is usually reassuring. It may also be driven by oestrogen exposure, pregnancy, or regular alcohol intake, which should be accounted for before attributing a favourable value to habitual physiology. Rarely, genetic hyperalphalipoproteinaemia produces very high levels; the association between extreme HDL elevation and benefit is not straightforward, so context matters.
Normal
A result within the reference interval does not exclude elevated cardiovascular risk, which is determined chiefly by the atherogenic, ApoB-bearing particle burden. ApoA-1 is best read with apolipoprotein B and the ApoB:ApoA-1 ratio and placed in the context of global risk assessment rather than treated as a standalone verdict.
Reduced
A low ApoA-1 indicates a diminished protective particle pool and correlates with heightened atherosclerotic risk, most commonly in the setting of metabolic syndrome, insulin resistance, hypertriglyceridaemia, smoking, or physical inactivity. Transient reductions accompany the acute-phase response. Very low values raise the possibility of inherited HDL deficiency such as ApoA-1 variants, familial hypoalphalipoproteinaemia, LCAT deficiency, or Tangier disease, warranting specialist evaluation.
Note: ApoA-1 is an immunoassay with platform-dependent intervals, so serial values are best compared within the same laboratory. It should be interpreted alongside apolipoprotein B, the lipid panel, and inflammatory status; it is a risk marker rather than a treatment target, and lipid-lowering therapy is directed principally at ApoB-containing lipoproteins.
Frequently asked questions
HDL-cholesterol measures the cholesterol carried inside HDL particles, whereas ApoA-1 counts the protective particles themselves, since each carries ApoA-1 but a variable cholesterol load. ApoA-1 therefore gives a more stable index of reverse-cholesterol-transport capacity, which is useful when a low HDL-cholesterol needs to be resolved into particle number versus cholesterol content.
How to access the ApoA-1 test
The ApoA-1 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. (2004)
- McQueen MJ, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. (verify citation/PMID). (2008)
- Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy. J Intern Med. (verify citation/PMID). (2006)
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. (verify citation/PMID). (2019)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Apo-B
The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…
cardiovascular
HDL-C
The HDL cholesterol test measures the cholesterol carried within high-density lipoprotein particles, a core component of the lipid profile and cardiovascular risk assessment. Low HDL-C is an independent risk marker, but HDL-C reflects cholesterol concentration rather than HDL function and is a risk marker, not a validated treatment target;